Molecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk.
Epidemiological studies suggest that medroxyprogesterone acetate (MPA) may increase the risk of HIV-1. The current studies were designed to identify potential underlying biological mechanisms.Human vaginal epithelial (VK2/E6E7), peripheral blood mononuclear (PBMC), and polarized endometrial (HEC-1-A...
Main Authors: | Susan C Irvin, Betsy C Herold |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4370479?pdf=render |
Similar Items
-
The Mechanism of Medroxyprogesterone Acetate
by: 詹維真
Published: (2003) -
Comparative study of the molecular mechanism of action of the synthetic progestins, Medroxyprogesterone acetate and Norethisterone acetate
by: Africander, Donita Jean
Published: (2010) -
Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice
by: Jocelyn M. Wessels, et al.
Published: (2019-10-01) -
The Canine Spermatogenic Suppression of Medroxyprogesterone acetate
by: Shu-Ching Wei, et al.
Published: (2004) -
Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice
by: Jocelyn M. Wessels, et al.
Published: (2021-02-01)